Inovio Pharmaceuticals (NASDAQ:INO) Price Target Lowered to $5.00 at HC Wainwright

Inovio Pharmaceuticals (NASDAQ:INO) had its target price reduced by HC Wainwright from $12.00 to $5.00 in a research report report published on Monday,Benzinga reports. They currently have a neutral rating on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Inovio Pharmaceuticals’ Q4 2024 earnings at ($1.03) EPS, FY2024 earnings at ($4.39) EPS, Q1 2025 earnings at ($1.08) EPS, Q2 2025 earnings at ($0.90) EPS, Q3 2025 earnings at ($0.78) EPS, Q4 2025 earnings at ($0.68) EPS and FY2025 earnings at ($3.35) EPS.

Several other analysts also recently issued reports on the company. Royal Bank of Canada cut their price objective on Inovio Pharmaceuticals from $7.00 to $6.00 and set a “sector perform” rating on the stock in a report on Friday, November 15th. Oppenheimer reduced their price target on shares of Inovio Pharmaceuticals from $33.00 to $15.00 and set an “outperform” rating for the company in a research report on Monday. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, Inovio Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $38.00.

Inovio Pharmaceuticals Stock Performance

Shares of NASDAQ:INO opened at $3.97 on Monday. Inovio Pharmaceuticals has a 1-year low of $3.85 and a 1-year high of $14.75. The company has a 50 day moving average price of $5.61 and a 200 day moving average price of $8.00.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp acquired a new position in Inovio Pharmaceuticals in the 2nd quarter worth about $661,000. Signature Estate & Investment Advisors LLC bought a new position in Inovio Pharmaceuticals during the second quarter valued at approximately $88,000. Rhumbline Advisers lifted its stake in Inovio Pharmaceuticals by 5,943.0% in the second quarter. Rhumbline Advisers now owns 38,494 shares of the biopharmaceutical company’s stock valued at $311,000 after acquiring an additional 37,857 shares during the last quarter. American Century Companies Inc. grew its position in Inovio Pharmaceuticals by 62.2% in the second quarter. American Century Companies Inc. now owns 31,565 shares of the biopharmaceutical company’s stock worth $255,000 after acquiring an additional 12,100 shares in the last quarter. Finally, Cornercap Investment Counsel Inc. acquired a new position in shares of Inovio Pharmaceuticals during the 2nd quarter worth $184,000. 26.79% of the stock is owned by hedge funds and other institutional investors.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.